Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
Amylin Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited announced that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications.
The agreement includes products to be developed from Amylin's pipeline, including pramlintide/metreleptin and davalintide, which are compounds currently in phase 2 development for treatment of obesity. The agreement also includes additional compounds from both companies' obesity research programs. Amylin will receive a one-time up-front payment of $75 million from Takeda and, over the term of the agreement and in relation to the compounds under the agreement, is eligible to receive additional payments upon achieving certain development, commercialization and sales-based milestones that could exceed $1 billion. The agreement also provides for future tiered, double-digit royalty payments to Amylin based on global product sales.
Under the terms of the agreement, Amylin will be responsible for executing development activities for potential products through phase 2 with the aim of regulatory approval in the U.S. Takeda will lead development activities beyond phase 2 in the U.S., and all development activities outside the U.S. In most instances, Amylin will be responsible for 20% of development costs associated with obtaining approval for products in the U.S. and Takeda will be responsible for 80% of such U.S. development costs. Takeda will be responsible for 100% of development costs associated with obtaining approval for products outside the U.S.
Takeda will lead product commercialization, both in the U.S. and outside the U.S., and will be responsible for 100% of commercialization costs. Amylin will have the option to co-commercialize the first two approved products in the U.S. and any follow-on products containing the identical active ingredients.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
ORCA Therapeutics licenses oncolytic adenovirus technology from VCN Biosciences
Neural Precursor Cells Induce Cell Death in Certain Brain Tumors - MDC and Charité Researchers Decipher the Mechanism of Action
Scientists wage fight against aging bone marrow stem cell niche
Hungry or full: It comes down to the atomic details - Insight into the molecular structure of an appetite-regulating cell receptor
Scienion GmbH - Berlin, Germany
Agilent Technologies - La Jolla, USA
Gene therapy to extend estrogen’s protective effects on memory
Magnetic bacteria as micropumps - Precisely transport cancer drugs to a tumor
A new approach to treating type I diabetes? Gut cells transformed into insulin factories - Study suggests a new approach could give patients the ability to make their own insulin-producing cells without a stem cell transplant
Cytomos welcomes new Director - £4 million investment sets path for commercialisation of groundbreaking cell analysis technology
Unique nasal microbiome
